×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Myeloma

Feature Video
Dr Noopur Raje opens this program with a brief discussion on the basics of multiple myeloma. She describes what the disease is, highlights key risk factors, and explains how she helps educate her patients on their diagnosis. Cynthia Harrington discusses her role as a nurse practitioner when working with multiple myeloma patients and why a team-based approach between healthcare providers and the patient is important.
Heather Millar
Researchers are considering whether some smoldering myelomas warrant treatment and which regimens are best.
Jessica Skarzynski
When diagnosing patients with multiple myeloma, it is important to identify the specific stage, mutations and risk level of the disease to determine the most effective treatment method, according to Jeffrey Wolf, M.D.
Chloe Spear, BSN, RN, OCN
A lack of vitamin D can have major impacts on myeloma treatment outomes. 
Katie Kosko
Four oncology nurses were recognized during the inaugural event for their efforts to prioritize the health of patients’ bone health during treatment.
DEBU TRIPATHY, M.D.
It takes a lot to call something a revolution in medicine ... The most important, of course, is its impact on people’s lives — particularly, a cure for illness or a major extension of life. A revolution also implies a sweeping cataclysmic change, one that is disruptive and boldly states that things will no longer be the same.
 
HEATHER MILLAR
In pretreated multiple myeloma, experimental CAR-T cell immunotherapy offers the potential for long-term — and possibly even permanent — remission.
Kristie L. Kahl
The Food and Drug Administration (FDA) granted approval to Darzalex (daratumumab) in combination with Velcade (bortezomib), melphalan and prednisone – also known as VMP – for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Brielle Urciuoli
One expert discusses current standard-of-care regimens as well as new combinations on the horizon for patients with myeloma who are not eligible to receive a stem cell transplant.
Katie Kosko
Nearly 17 years after the terror attack, researchers examine World Trade Center environmental factors and cases of multiple myeloma.
Brielle Urciuoli
There are a number of different treatment options for patients with relapsed myeloma, and it is important that patients and providers dicuss health history to determine which one is best.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable